Search

AEROBIKA* OPEP Device

A drug-free and easy to use device that can help open weak airways and to loosen mucus, so it can be coughed out.

View details

Patient Centered Considerations when Selecting an Oscillating Positive Expiratory Pressure (OPEP) Device

Efficacy is a major aspect when selecting an OPEP device for airway clearance.

This study was presented at the North American Cystic Fibrosis Conference 2022.

View details

view of aerocount dose counter from top angle

AEROCOUNT* Dose Counter (TMAI)

Provides patients with a visual indication of remaining medication in their pressurized Metered Dose Inhaler (MDI).

View details

aerocount etmai smart dose counter with bluetooth icon

AEROCOUNT* Smart Dose Counter (eTMAI)

Provides patients with a digital visual indication of remaining medication in their Metered Dose Inhaler (MDI).

View details

TRUZONE* Peak Flow Meter

A portable and inexpensive device that is used to measure how well air moves out of your lungs.

View details

How Might Choice of Salbutamol Metered Dose Inhaler (MDI) Type and Use of a Spacer Impact Drug Delivery and Emissions - Best for the Patient and Environment

As current MDIs contain hydrofluorocarbon propellants, it would be beneficial to find ways to reduce carbon emissions without compromising patient safety.

This lab study investigated a way to optimize the modelled lung dose per actuation while at the same time minimizing the carbon emissions from the MDI

View details

Patient-Centered Airway Clearance and the Role of OPEP

On June 9th 2026, the Australian Physiotherapy Association hosted a clinically focused webinar exploring Patient-Centered Airway Clearance strategies and the evolving role of Oscillating Positive Exploratory Pressure (OPEP) therapy in respiratory care.

IN THIS SESSION, WE WILL:

✓ Recognize the impact of unmanaged mucus hypersecretion

✓ Review evidence and guidelines supporting OPEP therapy use

✓ Explore differences across OPEP devices

✓ Apply insights from practical, real-world patient cases

View details

European Medical Journal: How a Novel Portable Spacer Benefits Patients with Respiratory Disease, the Healthcare System, and the Environment

View details

Inspiratory Profiles from Volunteer Adults who Have Read the Patient Instructions for Use for Two Passive Dry Powder Inhalers (DPIs) Compared with those from a Pressurized Metered Dose Inhaler with Valved Holding Chamber (pMDI+VHC)

This study was presented at the Drug Delivery to the Lungs, 2022.

View details

News and Publications

Recent News and Publications for Patients, Consumers and Health Professionals

View details

Using Functional Respiratory Imaging (FRI) to Compare Predicted Airway Deposition Between Pressurized Metered Dose Inhaler (pMDI) with AeroChamber Plus* Flow-Vu* Valved Holding Chamber (VHC) and Two Dry Powder Inhalers (DPIs) in a COPD patient

This study was presented at the Drug Delivery to the Lungs Conference, 2022.

View details

Dry Powder Inhalers (DPIs) vs Metered Dose Inhaler (MDI) with Valved Spacer : Using Functional Respiratory Imaging (FRI) to Assess Modelled Lung Deposition in a COPD patient

The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
The influence of inhalation flow profile was significant for one of the DPIs.

View details

Functional Respiratory Imaging (FRI) Shows Using AeroChamber Plus* Flow-Vu* Spacer with an MDI Provides More Effective Medication Delivery to the Lungs

A new study uses Functional Respiratory Imaging (FRI) to assess and compare the performance of a Metered Dose Inhaler (MDI) alone, an MDI with multiple brands of spacers, and a Dry Powdered Inhaler (DPI) alone. Using Functional Respiratory Imaging (FRI), the study explores the combined impact of inhaler mechanics, patient physiology and patient technique. Results suggest using an AeroChamber Plus* Flow-Vu* Spacer combined with an MDI results in superior medication delivery to the lungs, compared to the other spacer brands tested with MDIs, MDIs alone, and DPIs alone.

View details

Maximizing the benefit from the inhaler in order to minimize carbon footprint.

Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.

In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.

By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.

View details

Maximizing the benefit from the inhaler in order to minimize carbon footprint

Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.

In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.

By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.

View details

AeroChamber2go* Spacer Receives Prestigious GOOD DESIGN® Award

The AeroChamber2go* Spacer has been honored with a GOOD DESIGN® Award, the world’s oldest and most prestigious design program. The unique 2-in-1 spacer and protective inhaler case has been recognized for its innovative design, which benefits patients, the healthcare system, and the environment.

View details